XBIO
Xenetic Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.67
+0.86%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
Market Cap
$10.94M
MomentumView details →
1D Return
+0.86%
YTD Return
+114.75%
RSI (14)
89.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
Market Cap
$10.94M
RSI (14)
89.1
MomentumView details →
1D Return
+0.86%
YTD Return
+114.75%
SummaryUpdated Jun 1, 2026
Xenetic Biosciences, Inc. (NASDAQ:XBIO) is a clinical-stage biopharmaceutical company founded in 2005 and headquartered in Framingham, Massachusetts. The company went public in 2016 and focuses on developing innovative cancer treatments through its proprietary cell therapy platform and drug delivery technologies. Xenetic operates as a research and development-focused biotech company, advancing personalized cancer therapies while also leveraging its drug delivery platform through strategic partnerships with larger pharmaceutical companies.
Similar companies
Latest newsMore news →
Xenetic Biosciences reported financial results for the quarter ended June 30, 2026, and provided a corporate update on its DNase platform development strategy.28d agoPeriNess Ltd., collaboration partner of Xenetic Biosciences, received approval from the Israeli Ministry of Health to conduct an investigator-initiated study of DNase I in combination with anti-CD19 CAR T cells in large B-cell lymphoma.92d ago